RecruitingPhase 2NCT04205604
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
Studying Hyperinsulinemic hypoglycaemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Miguel Pampaloni
- Principal Investigator
- Miguel Hernandez Pampaloni, MD, PhDUniversity of California, San Francisco
- Intervention
- 18F-Fluoro Dopa Imaging(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2025
Study locations (1)
- University of California, San Francisco, San Francisco, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04205604 on ClinicalTrials.govOther trials for Hyperinsulinemic hypoglycaemia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT06208215RZ358 Treatment for Congenital HyperinsulinismRezolute
- RECRUITINGPHASE2NCT04732416HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)Hanmi Pharmaceutical Company Limited
- ACTIVE NOT RECRUITINGPHASE3NCT03941236Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital HyperinsulinismZealand Pharma
- RECRUITINGPHASE1NCT02021604Fluorodopa F 18 in Congenital Hyperinsulinism and InsulinomaCook Children's Health Care System